Neuromodulatory effect of GnRH from coeliac ganglion on luteal regression in the late pregnant rat

The GnRH/GnRH receptor system has been found in several extrapituitary tissues, although its physiological significance has not yet been well established. Taking into account that the peripheral neural system can act as a modulator of pregnancy corpus luteum, the objective was to physiologically investigate the presence of the GnRH system in coeliac ganglion (CG) and to analyse its possible involvement in luteal regression through the superior ovarian nerve (SON) at the end of pregnancy in the rat. The integrated ex vivo CG-SON-Ovary system of rats on day 21 of pregnancy was used. Cetrorelix (CTX), a GnRH receptor antagonist, was added into the ganglionic compartment while the control systems were untreated. Ganglionic GnRH release was detected under basal conditions. Then, the CTX addition in CG increased it, which would indicate the blockade of the receptor. In turn, CTX in CG caused an increase in ovarian progesterone release. Furthermore, the luteal cells showed an increase in the expression of Hsd3b1 and a decrease in the expression of Akr1c3 (progesterone synthesis and degradation enzymes, respectively), reduced TUNEL staining according to an increase in the antioxidant defence system activity and low lipid peroxide levels. The ovarian and ganglionic nitric oxide (NO) release increased, while the luteal nitrotyrosine content, measured as nitrosative stress marker, decreased. CTX in CG decreased the ovarian noradrenaline release. The present study provides evidence that GnRH from CG may trigger neuronal signals that promote the luteal regression in late pregnancy by affecting the release of NO and noradrenaline in the ovary.

Effects of Equine Chorionic Gonadotropin on Ovulatory and Luteal Characteristics of Mares Submitted to an P4-Based Protocol of Ovulation Induction With hCG

The aim of this study was to evaluate the effect of equine chorionic gonadotropin (eCG) at the end of progesterone (P4) treatment on follicular and luteal characteristics during transition period (TP) and reproductive breeding season (RP). A total of 13 crossbred mares were distributed in two experimental groups in the spring and summer (n = 26). The animals received intravaginal P4 (1.9 g) releasing device from D0 to D10. On removal of P4 device, the mares received 400 IU of eCG (eCG group) or saline solution (control group). Human chorionic gonadotropin (hCG; 1.750 IU) was administered (DhCG) as soon as ovulatory follicle (OF) ≥35 mm was detected. Ovarian ultrasonography was performed from D0 until 15 days after ovulation. Blood samples were collected on D0, D5, D10, DhCG, 9 days after ovulation (CL9D), and 13 days after ovulation (CL13D). P4 and estradiol concentrations were assessed by chemiluminescence. Data were compared by Tukey test at P < .05. Ovulation rate was similar (P = .096) between seasons (RP = 100%; TP = 70%) but occurred earlier (P = .015) in RP (34.8 ± 10.1 hours) compared with TP (42.0 ± 10.4 hours). Interactions between season and treatment were observed for OF diameter (mm) (RP/control = 36.2 ± 1.8ab; RP/eCG = 32.9 ± 2.8 b; TP/control = 32.2 ± 1.2 b; TP/eCG = 37.2 ± 1.9a; P = .004) and for corpus luteum (CL) diameter (mm) on CL13D (RP/control = 25.4 ± 3.5a; RP/eCG = 22.5 ± 1.8ab; TP/control = 21.6 ± 4.9 b; TP/eCG = 27.4 ± 4.3a; P = .023), although no differences were observed for serum P4 on CL13D (RP/control = 6.0 ± 3.1 ng/mL; RP/eCG = 5.8 ± 0.9 ng/mL; TP/control = 3.6 ± 2.7 ng/mL; TP/eCG = 5.1 ± 2.3 ng/mL; P = .429) or for day of structural CL regression (RP/control = 12.8 ± 1.9; RP/eCG = 12.1 ± 1.1; TP/control = 11.0 ± 1.7; TP/eCG = 13.2 ± 2.0; P = .102). The application of eCG at the moment of P4 implant removal seemed to increase the capacity of luteal maintenance during spring TP. However, eCG treatment was worthless during the breeding season.

Transcriptome analysis reveals differences in mechanisms regulating cessation of luteal function in pregnant and non-pregnant dogs

Background

In the domestic dog, corpora lutea (CL) are the only source of progesterone (P4), both in pregnant and non-pregnant cycles because there is no placental steroidogenesis. The absence of an endogenous luteolysin in absence of pregnancy results in long-lasting physiological pseudopregnancy, strongly contrasting with the acute luteolysis observed prepartum. The underlying biological mechanisms and the involvement of P4 signalling remain, however, not fully understood. Therefore, here, next-generation sequencing (RNA-Seq) was performed on CL from the late luteal phase and compared with normally luteolyzing CL collected at the prepartum P4 decrease.

Results

The contrast “luteal regression over luteolysis” yielded 1595 differentially expressed genes (DEG). The CL in late luteal regression were predominantly associated with functional terms linked to extracellular matrix (p = 5.52e-05). Other terms related to transcriptional activity (p = 2.45e-04), and steroid hormone signalling (p = 2.29e-04), which were more highly represented in late regression than during luteolysis. The prepartum luteolysis was associated with immune inflammatory responses (p = 2.87e-14), including acute-phase reaction (p = 4.10e-06). Immune system-related events were also more highly represented in CL derived from normal luteolysis (p = 7.02e-04), compared with those from dogs in which luteolysis was induced with an antigestagen (1480 DEG in total). Additionally, the withdrawal of P4 at mid-gestation resulted in 92 DEG; over-represented terms enriched in antigestagen-treated dogs were related to the inflammatory response (p = 0.005) or response to IL1 (p = 7.29e-05). Terms related to proliferation, e.g., centrosome organization (p = 0.002) and steroid metabolic processes (p = 0.001), prevailed at mid-gestation. Thereby, our results revealed the nature of luteotropic effects of P4 within canine CL. It appears that, even though they result in diminished steroidogenic output, the effect of antigestagens is more related to the withdrawal of P4 support than to the PGF2alpha-related inflammatory reaction observed at physiological parturition.

Conclusions

We report the differential gene expression associated with maintenance and cessation of luteal function in pregnant and non-pregnant dogs. Based on the differentially expressed genes, we indicate functional pathways and gene networks that are potentially involved in the underlying endocrine and molecular mechanisms. This study establishes future research directions that may be helpful in understanding some of the clinical conditions, such as luteal insufficiency, associated with negative pregnancy outcome in dogs.

Electronic supplementary material

The online version of this article (10.1186/s12864-017-4084-9) contains supplementary material, which is available to authorized users.

Effect of increasing GnRH and PGF2α dose during Double-Ovsynch on ovulatory response, luteal regression, and fertility of lactating dairy cows

Ovsynch-type synchronization of ovulation protocols have suboptimal synchronization rates due to reduced ovulation to the first GnRH treatment and inadequate luteolysis to the prostaglandin F2α (PGF2α) treatment before timed artificial insemination (TAI). Our objective was to determine whether increasing the dose of the first GnRH or the PGF2α treatment during the Breeding-Ovsynch portion of Double-Ovsynch could improve the rates of ovulation and luteolysis and therefore increase pregnancies per artificial insemination (P/AI). In experiment 1, cows were randomly assigned to a two-by-two factorial design to receive either a low (L) or high (H) doses of GnRH (Gonadorelin; 100 vs. 200 μg) and a PGF2α analogue (cloprostenol; 500 vs. 750 μg) resulting in the following treatments: LL (n = 263), HL (n = 277), LH (n = 270), and HH (n = 274). Transrectal ultrasonography and serum progesterone (P4) were used to assess ovulation to GnRH1, GnRH2, and luteal regression after PGF2α during Breeding-Ovsynch in a subgroup of cows (n = 651 at each evaluation). Pregnancy status was assessed 29, 39, and 74 days after TAI. In experiment 2, cows were randomly assigned to LL (n = 220) or HH (n = 226) treatment as described for experiment 1. For experiment 1, ovulation to GnRH1 was greater (P = 0.01) for cows receiving H versus L GnRH (66.6% [217/326] vs. 57.5% [187/325]) treatment, but only for cows with elevated P4 at GnRH1. Cows that ovulated to GnRH1 had increased (P < 0.001) fertility compared with cows that did not ovulate (52.2% vs. 38.5%); however, no effect of higher dose of GnRH on fertility was detected. The greater PGF2α dose increased luteal regression primarily in multiparous cows (P = 0.03) and tended to increase fertility (P = 0.05) only at the pregnancy diagnosis 39 days after TAI. Overall, P/AI was 47.0% at 29 days and 39.7% at 74 days after TAI; P/AI did not differ (P = 0.10) among treatments at 74 days (LL, 34.6%; HL, 40.8%; LH, 42.2%; HH, 40.9%) and was greater (P < 0.001) for primiparous cows than for multiparous cows (46.1% vs. 33.8%). For experiment 2, P/AI did not differ (P = 0.21) between H versus L treatments (44.2% [100/226] vs. 40.5% [89/220]). Thus, despite an increase in ovulatory response to GnRH1 and luteal regression to PGF2α, there were only marginal effects of increasing dose of GnRH or PGF2α on fertility to TAI after Double-Ovsynch.